A new study found that GeneSight CPGx precision medicine testing improves medication adherence and reduces polypharmacy in patients treated with antidepressants and antipsychotics. The test resulted in substantial cost savings of $1,036 per year per patient.
The GeneSight test combines multiple gene variations to predict patient responses to medications, improving treatment outcomes and healthcare resource utilization. The study found that patients on red category medications showed significantly less improvement in depressive symptoms.
The study will evaluate the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia, including clinical outcomes and cost benefits. The research aims to provide personalized treatment recommendations tailored to individual patient genetics.